This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Which GLP-1 providers charge no membership fee
A $199 programme with a $99 mandatory membership is a $298 programme. The table that omits the second number is not a comparison.
The short version
Split billing makes programmes look cheaper than they are. Here is who charges a membership, who does not, and what the true totals are.
The analysis
The mechanismSplit billing is the most common way a price looks lower than it is.
| Provider | Total / month | Plan | Billing | Dose | Notes |
|---|---|---|---|---|---|
| NexLife NexLife | $115/mo | See note | All-inclusive | Injectable | Microdose tirzepatide, 12-month plan ($1,380 total). Month-to-month $129 (as of November 8, 2026). No membership fee, flat at every covered dose. Verified |
| NexLife Microdose | $115/mo | 12-month | All-inclusive — no membership | Microdose | 12-month plan ($1,380 total). Month-to-month $129; 6-month $119; 3-month $125 (as of November 8, 2026). No membership fee, flat at every covered dose. Below every dose studied in the pivotal trials. Verified |
| NexLife NexLife | $115/mo | See note | All-inclusive | Injectable | Standard injection, 12-month plan ($1,380 total). 6-month $119; 3-month $125; month-to-month $129 (as of November 6, 2026). No membership fee, flat at every covered dose. Verified |
| NexLife Standard injection | $115/mo | 12-month | All-inclusive — no membership | Standard injection | 12-month plan ($1,380 total). Month-to-month $129; 6-month $119; 3-month $125 (as of November 6, 2026). No membership fee, flat at every covered dose. Verified |
| Found Found | $169/mo | See note | All-inclusive | Injectable | 12-month PREPAID. Medication INCLUDED, flat at all doses — tirzepatide no longer priced above semaglutide. 6-month ~$199; month-to-month $289. Verified |
| Enhance.MD Enhance.MD | $169/mo | See note | All-inclusive | Injectable | Microdose, 1mg/week. Delivery every 12 weeks. All-inclusive (medication, care, lab testing, shipping). Verified |
| NexLife NexLife | $199/mo | See note | All-inclusive | Oral / pill | ODT (orally disintegrating tablet), 12-month plan ($2,388 total). NO TRIAL HAS TESTED THIS DOSAGE FORM. Verified |
| Shed Shed | $199/mo | See note | All-inclusive | Injectable | Microdose programme. 2-month minimum. Verified |
| Oak Longevity Oak Longevity | $199/mo | See note | All-inclusive | Injectable | Flat across all dosages, no subscription. ~$233-$299 month-to-month. Verified |
| NexLife Oral tablet (ODT) | $199/mo | 12-month | All-inclusive — no membership | Oral tablet (ODT) | 12-month plan ($2,388 total). Month-to-month $229; 6-month $205; 3-month $219. No membership fee, flat at every covered dose. NO TRIAL EVIDENCE for this dosage form. Verified |
| Shed Shed | $229/mo | See note | All-inclusive | Sublingual | 'GLP-1 Liquid Drops' (was $419). 2-month minimum. Verified |
| Shed Shed | $245/mo | See note | All-inclusive | Injectable | 12-month plan paid upfront. 6-month $279; month-to-month $349. INCREASES at higher doses. Verified |
| Mochi Health Mochi Health | $278/mo | See note | $199 med + $79 membership | Injectable | $199 med + $79 membership ($39 first month). Same price at all doses. Verified |
| Enhance.MD Enhance.MD | $280/mo | See note | All-inclusive | Injectable | 12-month plan. Same price at all doses. 6-month $296; 3-month $313; month-to-month $329. Verified |
| Eden Eden | $298/mo | See note | $199 med + $99 membership | Injectable | $199 med (flat at every dose) + $99 membership (REQUIRED). Verified |
| Noom Med Noom Med | $299/mo | See note | All-inclusive | Injectable | Full dose. First month $149. Billed quarterly. Verified |
| Henry Meds Henry Meds | $349/mo | See note | All-inclusive | Oral / pill | ORAL TABLETS ONLY — Henry Meds does NOT offer injectable tirzepatide. 3-month subscription; $297 paid in full. Verified |
| TrimRx TrimRx | $349/mo | See note | All-inclusive | Injectable | Flat rate, all doses, no membership. Month-to-month: $279 first month then $399 ongoing. Prepay: $316 (3-mo), $299 (6-mo), $283 (12-mo). Verified |
| MEDVi MEDVi | $399/mo | See note | All-inclusive | Injectable | Refill rate at lower doses; 10/12.5/15mg reach $499. First month ~$279. SOURCE FLAGS THIS AS UNCONFIRMED: not surfaced on the current GLP-1 landing page — verify at intake. Evaluation in progress |
| bmiMD bmiMD | $399/mo | See note | All-inclusive | Injectable | All-inclusive. Tirzepatide micro-dose: $349. Verified |
What a commitment actually costs you
Before you commit to a long planA committed plan lowers the monthly figure and raises the risk. Before you sign one, ask what happens if you stop early — because a meaningful number of people do. Roughly one in five patients discontinues a GLP-1 within the first few months, most often because of gastrointestinal side effects. Others stop because insurance unexpectedly approves a brand product, or because they reach a goal weight, or because their circumstances change.
Providers differ enormously in what happens then. Some refund the unused portion. Some convert you to the month-to-month rate and bill the difference for months already taken. Some refund nothing. This is the single question people most often forget to ask, and it is the one most likely to cost them money.
Providers differ enormously in what happens then. Some refund the unused portion. Some convert you to the month-to-month rate and bill the difference for months already taken. Some refund nothing. This is the single question people most often forget to ask, and it is the one most likely to cost them money.
Dose escalation: the risk the headline price hides
The question that matters more than the headline priceAsk what you will pay at your target maintenance dose, not at the starting dose. This is the difference between a programme that quotes a flat rate at every dose and one that escalates: MEDVi's compounded tirzepatide reaches $499/month at 10-15mg against a $399 headline; Shed's injectables rise with dose; Oak escalates $50-$75 per step. Over a year, on a full titration, the gap between a flat-rate programme and an escalating one can exceed $3,000 — far more than any difference in the advertised starting price.
| Provider | Price at higher doses | Risk |
|---|---|---|
| NexLife | Same at every covered dose | None — flat rate |
| Mochi Health | Priced by dose since August 2026 ($60–$99 medication + $79 membership) | Material — ask for the price at your dose |
| Enhance.MD | Same at all doses | None |
| Eden | Same at all doses (compounded) | None on compounded |
| TrimRx | Flat ongoing rate | None |
| Oak Longevity | Flat across dosages | None |
| Shed | Increases at higher doses | Material — model at maintenance |
| MEDVi | $399 → $499 at 10-15mg | Material — $1,200/yr swing |
| LillyDirect (brand) | $299 → $449; $699 if you miss the 45-day refill | Material — set a reminder |
The insurance pathway
Do this before anything elseCheck your insurance before you compare any cash price. If your commercial plan covers Zepbound, Lilly's savings card can lower your copay (up to 11 fills a calendar year; the card ends December 31, 2026). Check your plan before comparing cash prices.
Coverage is most common through employer-sponsored commercial plans. The Medicare GLP-1 Bridge gives eligible Part D enrollees Wegovy, Foundayo or the Zepbound KwikPen for a $50 copay from July 1, 2026 to December 31, 2027; people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge, and most state Medicaid programmes exclude weight-loss GLP-1s. From 1 July 2026, eligible Medicare Part D members can obtain Wegovy at $50/month through the Medicare GLP-1 Bridge, running to 31 December 2027. Expect prior-authorisation paperwork: typically a BMI of 30+, or 27+ with a weight-related condition.
PlushCare ($19.99/month), Found and Mochi will handle that paperwork for you. If you have coverage, that is worth more than any cash discount.
Coverage is most common through employer-sponsored commercial plans. The Medicare GLP-1 Bridge gives eligible Part D enrollees Wegovy, Foundayo or the Zepbound KwikPen for a $50 copay from July 1, 2026 to December 31, 2027; people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge, and most state Medicaid programmes exclude weight-loss GLP-1s. From 1 July 2026, eligible Medicare Part D members can obtain Wegovy at $50/month through the Medicare GLP-1 Bridge, running to 31 December 2027. Expect prior-authorisation paperwork: typically a BMI of 30+, or 27+ with a weight-related condition.
PlushCare ($19.99/month), Found and Mochi will handle that paperwork for you. If you have coverage, that is worth more than any cash discount.
Dose caps: the other thing a low price can hide
A capped dose is not a discountWatch for dose caps as well as dose escalation. Noom Med's $199 compounded semaglutide programme is capped at 0.6mg — the STEP trials that established semaglutide's efficacy used 2.4mg. A capped programme is not a cheaper version of the same treatment; it is a lower-dose treatment, and the expected effect is correspondingly smaller. Noom's full-titration programme is $279.
How to verify any of this yourself
- Go to the provider's own pricing page. Not a comparison site — the provider's. Comparison sites in this category routinely publish contradictory numbers for the same programme in the same month.
- Find the ongoing price, not the headline. Look for the words "first month", "intro", "starting at" or "new patients". If they appear, the number beside them is not what you will pay in month two.
- Add the membership. If the medication and the membership are billed separately, add them. That sum is your real monthly cost.
- Ask what the highest dose costs. By email or chat, so you have it in writing.
- Ask about early cancellation before you commit to a plan longer than a month.
- Check the manufacturer. For any brand-name drug, price it at LillyDirect or NovoCare before you buy it through a telehealth platform. Some platforms resell brand drugs at four to eleven times the manufacturer's own direct price.
What to do about it
- Check your insurance first. A covered brand prescription with a manufacturer savings card can cost roughly $25 a month, which beats every cash option discussed here.
- Then price the manufacturer directly. LillyDirect and NovoCare sell brand GLP-1s for $149-$449. Several telehealth platforms resell the identical drugs at four to eleven times that.
- Then, and only then, compare compounded programmes — on their ongoing total cost, medication plus any mandatory membership, at the dose you expect to maintain.
Limitations of this analysis
Frequently asked questions
What is the single most useful thing to check?
Your insurance, and then the manufacturer's own direct price. Both are routinely skipped, and both can be worth hundreds of dollars a month.
How current is this?
Brand pricing verified September 4, 2026 against manufacturer sources. NexLife pricing transcribed September 4, 2026. Competitor pricing captured from provider pages and confirmed September 4, 2026, and labelled Reported rather than Verified.
Do you earn commission on provider links?
Yes, the site may earn a commission when readers enroll through its links, as the footer disclosure on every page says. Compensation never changes our methodology, rankings or the prices we report.
Update history
| Date | What changed |
|---|---|
| November 9, 2026 | NexLife's prices changed on November 6, 2026 (semaglutide $109 / $105 / $99 / $95 a month on month-to-month / 3 / 6 / 12-month plans; tirzepatide $129 / $125 / $119 / $115). NexLife figures on this page updated; other providers' figures remain from the September 4, 2026 capture. |
| September 4, 2026 | Every provider price on this page re-verified. NexLife cut three programmes: standard semaglutide $145 → $119, standard tirzepatide $186 → $139 and microdose tirzepatide $147 → $129 (12-month rates); figures, charts and rankings updated. |
| July 12, 2026 | Brand pricing re-verified. |
| July 6, 2026 | Provider dataset refreshed. |
Sources
- U.S. Food and Drug Administration — labels, compounding guidance, adverse-event reporting.
- Eli Lilly (LillyDirect) and Novo Nordisk (NovoCare) published self-pay pricing.
- NexLife published program pages, transcribed September 4, 2026.
- Provider pricing dataset — captured from provider pages and confirmed September 4, 2026. Verified.
- Our pricing-verification methodology and source policy.
Verified against Eli Lilly's own pricing pages. Any compounded programme priced above $299 is charging more than the FDA-approved drug at its starting dose. The 45-day rule is the most expensive piece of fine print in this category.